Lean Polycystic Ovarian Syndrome Has Better Responses toRecombinant Follicle-Stimulating Hormone Compared to ObesePCOS during Ovarian Stimulation for <i>In Vitro</i> Fertilization:A Cross-Sectional Study.

Background: fertilization (IVF) treatment. The purpose of our study was to compare ovarian response as well as IVF outcomes in lean and obese PCOS patients. The evaluation specifically focused on the utilization of recombinant follicle-stimulating hormone (rFSH) for ovarian stimulation. Materials and Methods: ). Data were obtained from our comprehensive database. This study included a total of 226 women diagnosed with PCOS, who underwent IVF between 2013 and 2023 at our fertility clinics. Women with alternative reproductive endocrinology disorders, frozen embryo cycles, canceled cycles, or those who failed to follow-up were excluded. Each of the lean and obese PCOS groups had 113 patients. Results: The mean age of the subjects was 32.7 ± 3.6 years. We found significant differences between the two groups in terms of the anti-müllerian hormone (AMH) levels (P=0.005), the initial dosage of rFSH (P<0.001), and cumulative doses of rFSH administered (P<0.001). However, the number of retrieved oocytes, endometrial thickness, cleavage rate, and pregnancy rates were comparable. Compared to the obese PCOS patients, the lean patients had higher AMH levels (8.80 vs. 6.85 ng/mL) and lower total dosages of rFSH (2128 ± 586 vs. 2752 ± 1136 IU). Conclusion: Individuals within the lean PCOS group exhibited elevated AMH levels and demonstrated a more favorable response to rFSH stimulation. Consequently, the lean PCOS group yielded more retrieved oocytes, while necessitating lower doses of rFSH stimulation compared to the obese PCOS group.